Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs MasTec Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while MasTec Inc trades at $212.75 (market cap $17.40B). The key difference: MasTec Inc is far larger — about 2.9× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and MasTec Inc for 23 Days on average.
| IOVA | MTZ | |
|---|---|---|
Market Cap | $6.04B | $17.40B |
Volume | 14,805,993 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $14.82 | $437.51 |
52-Week Low | $1.81 | $190.08 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $5.97B | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MasTec (MTZ) trades at $212.65, down 4.8% amid bearish technical signals, though recent earnings show mixed results with two beats and one miss. The company maintains strong analyst support with 88.9% buy ratings and a $408.58 consensus target, supported by record $21.4B backlog and infrastructure demand growth. Revenue reached $14.3B in 2025 with 3.07% net margin, while valuation ratios appear elevated with P/E of 34.5.
MTZ presents a compelling infrastructure growth story with AI and data center exposure, though premium valuation and weak cash flow pose near-term risks. The stock's current discount to analyst targets offers potential upside if execution improves, but investors should monitor communications segment softness and margin pressures in a competitive contracting environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
